It is a great honour and pleasure for me to have been appointed as the new CEO of GALVmed. I join the organisation at a moment where GALVmed can look back proudly onto 10 years of successful operations and has established a solid foundation of experienced staff, strong partners and good funding. Let us stop […]

GALVmed has received funding approval totalling to US$ 19 million for the Phase 3 programme on Improved Tools for the Control of Animal African Trypanosomosis (Tryps 3). The main objective of the programme, which is co-funded by the UK Government and Bill & Melinda Gates Foundation, is to commercially develop a registered therapeutic trypanocidal product […]

In September 2018 Dr Peter Wells retired from GALVmed’s Board of Trustees. Peter became involved with GALVmed initially through the Expert Scientific Advisory Committee before involvement in the governance of GALVmed early 2011. After a brief period as interim CEO Peter was formally appointed as a trustee in April 2012. During his time as trustee […]

GALVmed representatives Jeremy Salt and Mark Rweyemamu are this week attending a meeting in Vienna, Austria, to launch the Peste des petits ruminants Global Research and Expertise Network (PPR-GREN). The PPR-GREN network was established and endorsed in 2015 to support a global strategy to eradicate PPR. Peste des petits ruminants,or simply known as PPR, was […]

Jeremy Salt, our Chief Scientific Officer attended two meetings highlighted in this March edition of  STAR-IDAZ. Jeremy is a member of the scientific committee of International Research Consortium on Animal Health. Read more.

GALVmed’s Market Development & Access (MD&A) department in South Asia has been working with the Jeevika Trust recently to deliver training in goat rearing in Bihar, India. The trust was aware of GALVmed’s work and its expertise in animal health and management. It approached the organisation through the Aga Khan Foundation (AKF) to train their officials on goat health […]

        Release date: 24 May 2017 EDINBURGH, UK, May 24, 2017 – Small ruminant experts attending this month’s International Sheep Veterinary Congress in Harrogate are being encouraged to enter a US $30 million prize competition to develop a brucellosis vaccine to improve the livelihoods of smallholder farmers in developing countries. The Brucellosis […]

(Johannesburg, 11 May 2017) In a globalising world where clusters of countries increasingly face the same challenges and seek closer cooperation to deal with these issues together, great gains can be made by harmonising approaches to problem solving and avoiding duplication of efforts among countries in the same region. One such area is the registration of […]

LEUVEN, Belgium, May 17th, 2017 — ViroVet NV, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce a collaboration with GALVmed. Under the collaboration, ViroVet will extend its vaccine pipeline to include novel vaccines for small ruminants. Since its capital increase in December […]

(15th February 2015) GALVmed recently held a workshop Nairobi (19-20 January 2017) to discuss ongoing research to improve the East Coast Fever (ECF) vaccine. The vaccine, commonly known as Infection and Treatment Method (ITM)  was developed in mid-70s and since then new tools have been developed   to characterise the vaccine strains/stocks and provide new knowledge […]